Lyra Therapeutics (Lyra Therapeutics) Cash-to-Debt : 2.30 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Lyra Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Lyra Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2024 was 2.30.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Lyra Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Lyra Therapeutics's Cash-to-Debt or its related term are showing as below:

LYRA' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.3 Med: 30.52 Max: No Debt
Current: 2.3

During the past 6 years, Lyra Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 2.30. And the median was 30.52.

LYRA's Cash-to-Debt is ranked worse than
65.42% of 1492 companies
in the Biotechnology industry
Industry Median: 6.85 vs LYRA: 2.30

Lyra Therapeutics Cash-to-Debt Historical Data

The historical data trend for Lyra Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Lyra Therapeutics Cash-to-Debt Chart

Lyra Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

2.95

30.58

31.49

23.44

3.82

Lyra Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															39.55	68.81	16.30	3.82	2.30

Competitive Comparison of Lyra Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Lyra Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lyra Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lyra Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Lyra Therapeutics's Cash-to-Debt falls into.

Lyra Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Lyra Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	102.753	/	(5.434	+	21.447)
	=	3.82

Lyra Therapeutics's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	87.118	/	(4.504	+	33.356)
	=	2.30

Lyra Therapeutics (NAS:LYRA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Lyra Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Lyra Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Lyra Therapeutics (Lyra Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyra Therapeutics Inc (NAS:LYRA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Arsenal Way, Watertown, MA, USA, 02472

Website

https://lyratherapeutics.com

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

Executives

Harlan Waksal	director, officer: Executive Chair	WAKSAL CONSULTING LLC, 7 NORTH WILLOW STREET, SUITE 6, MONTCLAIR NJ 07042
Nbvm Gp, Llc	10 percent owner	950 WINTER STREET, SUITE 4600, WALTHAM MA 02451
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Edward T Anderson	director, 10 percent owner	950 WINTER ST SUITE 4600, WATHAM MA 02451
John E Bishop	officer: Chief Technology Officer	675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Richard Nieman	officer: Chief Medical Officer	C/O LYRA THERAPEUTICS, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
C Ann Merrifield	director
James R Tobin	director	C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Jason Cavalier	officer: Chief Financial Officer	C/O LYRA THERAPEUTICS, INC., 1480 ARSENAL WAY, WATERTOWN MA 02472
Snyderman Nancy Lynn Md	director	37 PHEASANT HILL ROAD, PRINCETON NJ 08540
Pamela E. Nelson	officer: Senior VP, Regulatory Affairs	C/O LYRA THERAPEUTICS, INC., 1480 ARSENAL WAY, WATERTOWN MA 02472
Robert E. Richard	officer: SVP of R&D	C10 LYRA THERAPEUTICS, INC., 1480 ALSENAL WAY, WATERTOWN MA 02472
Soleus Private Equity Fund I, L.p.	10 percent owner	C/O SOLEUS PRIVATE EQUITY GP I, LLC, 104 FIELD POINT ROAD, 2ND FLOOR, GREENWICH CT 06830
Soleus Capital, Llc	10 percent owner	104 FIELD POINT ROAD, FLOOR 2, GREENWICH CT 06830
Polaris Venture Partners Special Founders' Fund V, L.p.	10 percent owner	ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210